Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Clin Respir J ; 8(1): 41-4, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23711195

ABSTRACT

INTRODUCTION: In patients with refractory pleural effusion or pneumothorax, fever and elevated level of white blood cell count (WBC) are frequently observed after chemical pleurodesis with intrapleural injection of OK-432, which make it difficult to differentiate whether it was from the side effects of OK-432 or concurrent bacterial infection. OBJECTIVE: Procalcitonin (PCT) levels were measured before and after pleurodesis so as to discuss whether PCT is useful for distinguishing between the side effects of OK-432 and concurrent bacterial infection. METHOD: Twenty-six patients with refractory pleural effusion or pneumothorax who underwent chemical pleurodesis with intrapleural injection of OK-432 at the First Affiliated Hospital of Sun Yat-sen University between August 2010 and August 2012 were included in our study. Levels of PCT and WBC were measured before and after pleurodesis. RESULT: Of all 26 patients, 22 patients were with refractory pleural effusion, and the other four were with pneumothorax. The median serum levels of PCT and WBC elevated from 0.155 to 1.470 ng/mL (P = 0.009) and from 5.920 to 10.475 × 10(9) /L (P = 0.000), respectively. No patient was given antibiotics and fever subsided. CONCLUSION: Intrapleural injection of OK-432 could increase the serum level of PCT and WBC with no bacterial infection. The serum PCT level may not be useful to distinguish whether fever was caused by the side effects of OK-432 or concurrent bacterial infection.


Subject(s)
Antineoplastic Agents/administration & dosage , Calcitonin/blood , Picibanil/administration & dosage , Pleural Effusion/drug therapy , Pleurodesis , Pneumothorax/drug therapy , Protein Precursors/blood , Adult , Aged , Bacterial Infections/epidemiology , Calcitonin Gene-Related Peptide , Comorbidity , Female , Humans , Male , Middle Aged , Pleural Effusion/blood , Pleural Effusion/epidemiology , Pneumothorax/blood , Pneumothorax/epidemiology , Young Adult
2.
Braz. j. infect. dis ; 16(6): 531-539, Nov.-Dec. 2012. ilus, tab
Article in English | LILACS | ID: lil-658923

ABSTRACT

OBJECTIVE: To investigate the clinical features, management, and prognosis of pulmonary cryptococcosis in non-acquired immunodeficiency syndrome (AIDS) patients. METHOD: 24 cases of pulmonary cryptococcosis with accurate pathological diagnosis were retrospectively studied. RESULTS: 15 male patients and nine female patients were diagnosed at the first affiliated hospital of Sun Yat-sen University from November 1999 to November 2011. The mean age at the time of diagnosis was 44.2 ± 11.3 years (range: 24 to 65 years). Among these patients, 13 had other comorbidities. 15 were symptomatic and the other nine were asymptomatic. The most common presenting symptoms were cough, chest tightness, expectoration, and fever. None had concurrent cryptococcal meningitis. The most frequent radiologic abnormalities on chest computed tomography (CT) scans were solitary or multiple pulmonary nodules, and masses or consolidations, and most lesions were located in the lower lobes. All patients had biopsies for the accurate diagnosis. Among the 24 patients, nine patients underwent surgical resections (eight had pneumonectomy via thoracotomy and one had a pneumonectomy via thoracoscopy). Five of the patients who underwent surgery also received antifungal drug therapy (fluconazole) for one to three months after the surgery. The other 15 only received antifungal drug therapy (fluconazole or voriconazole) for three to six months (five patients are still on therapy). The follow-up observation of 19 patients who had already finished their treatments lasted from two to 11 years, and there was no relapse, dissemination, or death in any of these patients. CONCLUSION: Non-AIDS patients with pulmonary cryptococcosis have a good prognosis with appropriate management.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Cryptococcosis/diagnosis , Cryptococcus neoformans/isolation & purification , Lung Diseases, Fungal/diagnosis , Antifungal Agents/therapeutic use , Combined Modality Therapy , Cryptococcosis/therapy , Fluconazole/therapeutic use , Lung Diseases, Fungal/microbiology , Lung Diseases, Fungal/therapy , Prognosis , Pyrimidines/therapeutic use , Retrospective Studies , Thoracotomy , Tomography, X-Ray Computed , Triazoles/therapeutic use
3.
Braz J Infect Dis ; 16(6): 531-9, 2012.
Article in English | MEDLINE | ID: mdl-23154046

ABSTRACT

OBJECTIVE: To investigate the clinical features, management, and prognosis of pulmonary cryptococcosis in non-acquired immunodeficiency syndrome (AIDS) patients. METHOD: 24 cases of pulmonary cryptococcosis with accurate pathological diagnosis were retrospectively studied. RESULTS: 15 male patients and nine female patients were diagnosed at the first affiliated hospital of Sun Yat-sen University from November 1999 to November 2011. The mean age at the time of diagnosis was 44.2±11.3 years (range: 24 to 65 years). Among these patients, 13 had other comorbidities. 15 were symptomatic and the other nine were asymptomatic. The most common presenting symptoms were cough, chest tightness, expectoration, and fever. None had concurrent cryptococcal meningitis. The most frequent radiologic abnormalities on chest computed tomography (CT) scans were solitary or multiple pulmonary nodules, and masses or consolidations, and most lesions were located in the lower lobes. All patients had biopsies for the accurate diagnosis. Among the 24 patients, nine patients underwent surgical resections (eight had pneumonectomy via thoracotomy and one had a pneumonectomy via thoracoscopy). Five of the patients who underwent surgery also received antifungal drug therapy (fluconazole) for one to three months after the surgery. The other 15 only received antifungal drug therapy (fluconazole or voriconazole) for three to six months (five patients are still on therapy). The follow-up observation of 19 patients who had already finished their treatments lasted from two to 11 years, and there was no relapse, dissemination, or death in any of these patients. CONCLUSION: Non-AIDS patients with pulmonary cryptococcosis have a good prognosis with appropriate management.


Subject(s)
Cryptococcosis/diagnosis , Cryptococcus neoformans/isolation & purification , Lung Diseases, Fungal/diagnosis , Adult , Aged , Antifungal Agents/therapeutic use , Combined Modality Therapy , Cryptococcosis/therapy , Female , Fluconazole/therapeutic use , Humans , Lung Diseases, Fungal/microbiology , Lung Diseases, Fungal/therapy , Male , Middle Aged , Prognosis , Pyrimidines/therapeutic use , Retrospective Studies , Thoracotomy , Tomography, X-Ray Computed , Triazoles/therapeutic use , Voriconazole , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...